Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
44 hedge funds and large institutions have $225M invested in Constellation Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 4 closing their positions.
264% more capital invested
Capital invested by funds: $61.9M → $225M (+$163M)
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
19% more funds holding
Funds holding: 37 → 44 (+7)
4.33% more ownership
Funds ownership: 60.03% → 64.36% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.56M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.44M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$706K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$680K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.43M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$318K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$269K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$108K |
| 5 |
Morgan Stanley
New York
|
-$57.8K |
CNST Hedge Fund Activity: Q1 2019 in Review
44 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q1 2019, worth a combined $225M — up 264% from $61.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CNST positions and 4 closed out — a net gain of 7 holders — while 17 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $5.56M. The largest seller was Deerfield Management, cutting an estimated $3.43M.
- 44 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q1 2019, up from 37 in Q4 2018.
- Funds reported $225M of Constellation Pharmaceuticals, Inc. stock for Q1 2019, up 264% quarter-over-quarter.
- 11 funds opened new Constellation Pharmaceuticals, Inc. positions in Q1 2019 and 4 closed out, a net change of +7 holders.
- The largest Constellation Pharmaceuticals, Inc. buyer in Q1 2019 was BlackRock, an estimated $5.56M added.
- The largest Constellation Pharmaceuticals, Inc. seller in Q1 2019 was Deerfield Management, an estimated $3.43M sold.
Based on aggregated 13F filings for Q1 2019.